Terns Pharmaceuticals, Inc. Accounts Payable

Accounts Payable of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Accounts Payable growth rates and interactive chart. Accounts payable (AP) represents a company's obligation to pay off a short-term debt to its creditors or suppliers. Accounts payable are amounts due to vendors or suppliers for goods or services received that have not yet been paid for. The sum of all outstanding amounts owed to vendors is shown as the accounts payable balance on the company's balance sheet. The increase or decrease in total AP from the prior period appears on the cash flow statement.


Highlights and Quick Summary

  • Accounts Payable for the quarter ending March 31, 2022 was $1.68 Million (a -21.07% decrease compared to previous quarter)
  • Year-over-year quarterly Accounts Payable decreased by -0.59%
  • Annual Accounts Payable for 2021 was $2.13 Million (a 127.38% increase from previous year)
  • Annual Accounts Payable for 2020 was $935 Thousand (a -42.85% decrease from previous year)
  • Annual Accounts Payable for 2019 was $1.64 Million (a 78.99% increase from previous year)
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Accounts Payable of Terns Pharmaceuticals, Inc.

Most recent Accounts Payableof TERN including historical data for past 10 years.

Interactive Chart of Accounts Payable of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Accounts Payable for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $1.68
2021 $2.13 $1.58 $1.69 $4.25 $2.13
2020 $0.94 $-0.25 $0.94
2019 $1.64 $1.64
2018 $0.91

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.